Evidence map›Paper›PMID 33632171›Full record

ArticleBMC infectious diseases2021

Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK.

Janine Makaronidis, Chloe Firman, Cormac G Magee, Jessica Mok, Nyaladzi Balogun, Matt Lechner, Alisia Carnemolla, Rachel L Batterham

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04377815 (FORECAST Study), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04377815 completednot on this map

FORECAST Study: Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste

TypeobservationalSponsorUniversity College, LondonRan2020 to 2020Enrolled569ConditionsCOVID-19, AnosmiaArmsGeneral Public cohort
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Parosmia: Pathophysiology and Management.Current allergy and asthma reports · 2025
    Review
  7. Article
  8. Article
  9. COVID-19-related chemosensory changes: Findings from a prospective national database.World journal of otorhinolaryngology - head and neck surgery · 2024
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Janine MakaronidisUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK.
Chloe FirmanUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK.
Cormac G MageeUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK.
Jessica MokUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK.
Nyaladzi BalogunUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK.
Matt LechnerUCL Cancer Institute, University College London, London, UK.
Alisia CarnemollaUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK.
Rachel L BatterhamUCL Centre for Obesity Research, Division of Medicine, University College London, London, UK. r.batterham@ucl.ac.uk.ORCID http://orcid.org/0000-0002-5477-8585
University College Hospital · GBNational Institute for Health Research · GBBarts Health NHS Trust · GBUniversity College London · GB

Funding

Health Technology Assessment Programme RP-2015-06-005National Institute for Health Research BRC751Sir Jules Thorn Charitable Trust NA
6 · The paper itself

Abstract

backgroundLoss of smell and/or taste are cardinal symptoms of COVID-19. 'Long-COVID', persistence of symptoms, affects around one fifth of people. However, data regarding the clinical resolution of loss of smell and/or taste are lacking. In this study we assess smell and taste loss resolution at 4-6 week follow-up, aim to identify risk factors for persistent smell loss and describe smell loss as a feature of long-COVID in a community cohort in London with known SARS-CoV-2 IgG/IgM antibody status. We also compare subjective and objective smell assessments in a subset of participants.

methodsFour hundred sixty-seven participants with acute loss of smell and/or taste who had undergone SARS-CoV-2 IgG/IgM antibody testing 4-6 weeks earlier completed a follow-up questionnaire about resolution of their symptoms. A subsample of 50 participants completed an objective olfactory test and results were compared to subjective smell evaluations.

resultsPeople with SARS-CoV-2 antibodies with an acute loss of sense of smell and taste were significantly less likely to recover their sense of smell/taste than people who were seronegative (smell recovery: 57.7% vs. 72.1%, p = 0.027. taste recovery 66.2% vs. 80.3%, p = 0.017). In SARS-CoV-2 positive participants, a higher percentage of male participants reported full resolution of smell loss (72.8% vs. 51.4%; p < 0.001) compared to female participants, who were almost 2.5-times more likely to have ongoing smell loss after 4-6 weeks (OR 2.46, 95%CI 1.47-4.13, p = 0.001). Female participants with SARS-CoV-2 antibodies and unresolved smell loss and unresolved taste loss were significantly older (> 40 years) than those who reported full resolution. Participants who experienced parosmia reported lower smell recovery rates and participants with distorted taste perception lower taste recovery rates. Parosmia had a significant association to unresolved smell loss (OR 2.47, 95%CI 1.54-4.00, p < 0.001).

conclusionAlthough smell and/or taste loss are often transient manifestations of COVID-19, 42% of participants had ongoing loss of smell, 34% loss of taste and 36% loss of smell and taste at 4-6 weeks follow-up, which constitute symptoms of 'long-COVID'. Females (particularly > 40 years) and people with a distorted perception of their sense of smell/taste are likely to benefit from prioritised early therapeutic interventions. TRIALS REGISTRATION: ClinicalTrials.gov NCT04377815 Date of registration: 23/04/2020.

Indexed as

AdultAgeusiaAntibodies, ViralCohort StudiesCOVID-19FemaleHumansImmunoglobulin MLondonMaleMiddle AgedOlfaction DisordersSARS-CoV-2Sex FactorsSmellSurveys and QuestionnairesAntibodies, ViralImmunoglobulin MCOVID-19Long COVID-19SARS-CoV-2 IgG/IgMSmell lossSmell recoveryTaste lossTaste recovery

Identifiers

PMID33632171
PMCPMC7905973
OpenAlexW3126898659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.